<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628380</url>
  </required_header>
  <id_info>
    <org_study_id>CHORINE 2012-002616-22</org_study_id>
    <nct_id>NCT01628380</nct_id>
  </id_info>
  <brief_title>Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer</brief_title>
  <acronym>CHORINE</acronym>
  <official_title>Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Organization for Strategies &amp; Solutions (CLIOSS), former Nerviano Medical Sciences (http://www.nervianoms.com/en/)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onlus Cancro Primo Aiuto (http://www.cpaonlus.it/)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the Study is to compare two-years disease-free survival of Cytoreductive Surgery (CRS)
      and Hyperthermic IntraPEritoneal Chemotherapy (HIPEC, CDDP+Paclitaxel) vs CRS alone in Stage
      IIIC unresectable epithelial tubal/ovarian cancer with partial or complete response after 3
      cycles of 1st line chemotherapy (CBDCA +Paclitaxel).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible: Female adult women (18 to 70 years old) patients, with epithelial ovarian/tubal
      (FIGO stage IIIC) with a Fagotti modified Laparoscopic Scoring System ≥ 4 who will show a
      complete or partial clinical response(RECIST 1.1) after 3 cycles of neoadjuvant chemotherapy
      (Carboplatin+Paclitaxel).

      Duration of recruitment: 2 years. Sample size has been calculated to reach a confidence level
      of 95% with a power of 80%, considering a 45% and 75% disease-free survival at 2 years in CRS
      and CRS+HIPEC group respectively.

      Sample size will be 47 patients for each group. After CRS, only patients with adequate
      cytoreduction (CC 0-1, residual tumor ≤ 2.5mm) will be randomized. Patients with suboptimal
      cytoreduction (CC 2-3, residual tumor &gt; 2.5mm) are not suitable for randomization.

      The drug schedule elected in the current study is Cisplatin (CDDP) (100 mg/m2 of body surface
      area) + Paclitaxel (175mg/m2 of body surface area).

      Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature:
      42°C. Primary Endpoint: 2-years disease-free survival.

      Secondary Endpoints:

      1-year, 3- and 5-years disease-free survival;

      1 month, 1-year, 3- and 5-years overall survival; toxicity induced by HIPEC using the NCI CTC
      criteria; one month and six months morbidity; duration of operation; return of bowel
      function; length of hospital stay; return to normal activity; six months and one year QOL,
      using the SF-36 v1.0; percentage of patients in both arms completing the scheduled
      postoperative chemotherapy; Subgroup analysis: PCI ≤ 15; pts. ≤ 40yrs.

      Main topics of this Study:

      Focused only on upfront treatment of primary disease. Select platinum-sensible patients
      (responders to platinum-based neoadjuvant chemotherapy).

      Take advantage of NACT to maximize chances for cytoreduction. Standardized strategy for CRS:
      radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm
      residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection,
      etc.). Pelvic and peri-aortic lymphadenectomy is not chosen as standard procedure, but should
      warrant adequate staging.

      Compare only the effect of HIPEC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative morbidity and mortality</measure>
    <time_frame>1 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Chemotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>percentage of patients in both arms completing the scheduled postoperative chemotherapy and time elapsed to start postoperative chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1, 3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>CRS + HIPEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cytoreductive Surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive Surgery and HIPEC</intervention_name>
    <description>CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).
HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C.</description>
    <arm_group_label>CRS + HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CRS alone</intervention_name>
    <description>CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)</description>
    <arm_group_label>CRS alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female adult women (18 to 70 years old) patients, with EOC (FIGO stage IIIc) with a
             Fagotti modified Laparoscopic Scoring System ≥ 4 who will show a complete clinical
             response (cCR) or partial clinical response (cPR) after 3 cycles
             (Carboplatin+Paclitaxel) of neoadjuvant chemotherapy;

          -  performance status (ECOG) 0, 1 or 2;

          -  signed informed consent.

        Exclusion Criteria:

          -  refusing to sign an informed consent;

          -  age &gt; 70 years and age &lt;18 years;

          -  BMI &gt; 35;

          -  impossibility of an adequate follow-up;

          -  presence of other active neoplasms;

          -  active infection or other concurrent medical condition that could interfere in the
             ability of patients to receive the proposed treatment according to protocol;

          -  extraabdominal metastases (Stage IV) ;

          -  performance status (ECOG)&gt;2;

          -  complete bowel obstruction;

          -  Abnormal bone marrow indices or renal and liver function;

          -  ASA IV or V.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Ansaloni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luca Ansaloni, MD</last_name>
    <phone>+390352673477</phone>
    <email>lansaloni@hpg23.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marco Lotti, MD</last_name>
    <phone>+390352673477</phone>
    <email>mlotti@hpg23.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingo B. Runnebaum, MD, MBA</last_name>
      <email>INGO.RUNNEBAUM@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Ingo B. Runnebaum, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII (former Ospedali Riuniti)</name>
      <address>
        <city>Bergamo</city>
        <state>Bg</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Ansaloni, MD</last_name>
      <phone>+390352673477</phone>
      <email>lansaloni@hpg23.it</email>
    </contact>
    <contact_backup>
      <last_name>Marco Lotti, MD</last_name>
      <phone>+390352673477</phone>
      <email>mlotti@hpg23.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luca Ansaloni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna - Bologna (Bo)</name>
      <address>
        <city>Bologna</city>
        <state>Bo</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierandrea Deiaco, MD</last_name>
      <phone>+390516364426</phone>
      <email>pierandrea.deiaco@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Pierandrea Deiaco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Di Parma - Parma (Pr) Oncologia Chirurgica</name>
      <address>
        <city>Parma</city>
        <state>Pr</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto Catena, MD</last_name>
      <phone>+390521703940</phone>
      <email>faustocatena@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fausto Catena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>POLICLINICO UNIVERSITARIO GEMELLI DI ROMA - ROMA (RM) GINECOLOGIA E OSTETRICIA Dipartimento per la Tutela della Salute della Donna e della Vita Nascente</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Scambia, MD</last_name>
      <phone>+390630156279</phone>
      <email>clinicaltrials@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Scambia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ansaloni L, De Iaco P, Frigerio L. Re: &quot;cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase II trial.&quot; - Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study. Gynecol Oncol. 2012 Apr;125(1):279-81. doi: 10.1016/j.ygyno.2012.01.001. Epub 2012 Jan 9.</citation>
    <PMID>22233688</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>Luca Ansaloni MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIPEC</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Cytoreductive Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

